Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 9.


Osanlou, Rostam, Walker, Lauren ORCID: 0000-0002-3827-4387, Hughes, Dyfrig A ORCID: 0000-0001-8247-7459, Burnside, Girvan ORCID: 0000-0001-7398-1346 and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2022) Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ OPEN, 12 (7). e055551-.


Asiimwe, Innocent G ORCID: 0000-0002-1196-1822, Zhang, Eunice J ORCID: 0000-0003-1813-2207, Osanlou, Rostam, Krause, Amanda, Dillon, Chrisly, Suarez-Kurtz, Guilherme, Zhang, Honghong, Perini, Jamila A, Renta, Jessicca Y, Duconge, Jorge
et al (show 12 more authors) (2020) Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis. Clinical Pharmacology and Therapeutics, 107 (6). pp. 1420-1433.


Khoo, Saye H ORCID: 0000-0002-2769-0967, FitzGerald, Richard, Saunders, Geoffrey, Middleton, Calley, Ahmad, Shazaad, Edwards, Christopher J, Hadjiyiannakis, Dennis, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186
et al (show 80 more authors) (2022) Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases, 23 (2). pp. 183-195.


Liu, Xinxue, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin
et al (show 50 more authors) (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 87 (1). pp. 18-26.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 84 (6). pp. 795-813.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2023) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022). JOURNAL OF INFECTION, 86 (5). pp. 540-541.


Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate
et al (show 44 more authors) (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. LANCET, 398 (10318). pp. 2258-2276.


Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 45 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. LANCET INFECTIOUS DISEASES, 22 (8). pp. 1131-1141.


Asiimwe, Innocent G ORCID: 0000-0002-1196-1822, Zhang, Eunice J ORCID: 0000-0003-1813-2207, Osanlou, Rostam, Jorgensen, Andrea L ORCID: 0000-0002-6977-9337 and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2021) Warfarin dosing algorithms: A systematic review. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87 (4). pp. 1717-1729.

This list was generated on Mon Feb 12 11:46:05 2024 GMT.